AI Integration Push by Governments and Research Institutes to Transform Quality of Care for Cardiac Patients

Integration of artificial intelligence (AI) is picking up pace in drug development. AI is used for various aspects, starting from the discovery of compounds exhibiting life-saving properties to the identification of patients needing care.

In the last few years, AI also has shown potential use cases in transforming patient care. Especially after the pandemic, implementation of AI and advanced machine learning has surged for remotely monitoring patients and keeping a better track of their healthcare, offering patient-specific treatment, and identifying abnormalities.

In 2021, the Biden Administration formed an AI task force to offer easy access to government data and improve access to educational tools and critical resources to bolster AI innovation. This act covers a USD 250 million budget for a period of half a decade. It also builds on 2020 legislation.

Thanks to the increased funding and nationwide spotlight on AI-based advances, both wearables, and AI technology will soon expand to accommodate predictive capabilities. This also has encouraged research, testing AI capabilities in transforming care and treatment administered to cardiac patients.

For instance, a recent study by Mayo Clinic showed that AI can be used to identify patients at greater risk of cognitive decline or stroke. For instance, AI-enabled electrocardiography has recently proven successful in identifying brief episodes of atrial fibrillation.

The study conducted by Mayo Clinic offered evidence that the algorithm can help in identifying patients who are at greater risk of cognitive decline. Leading international institutions such as the National Institutes of Health and the National Institute of Aging supported the research.

In another research initiative, “Digitaler Herz-OP”, which can be translated as Digital Heart Surgery, engineers and physicians at the Munich Institute of Robotics and Machine Intelligence (MIRMI) and the German Heart Center Munich (DHM) worked closely together to develop high precision instruments for cardiac catheter lab, operating room, and the intensive care unit.

• About
• Latest Posts

Sabestian Miller

Associate Editor at Pharma Geek

Sabestian is an Associate Editor of drug development and health industries at Pharma Geek. Sabestian is a writer based in the India. He graduated from the University of Sussex with a BA in Media Practice, having specialized in screenwriting. He maintains a focus on anxiety disorders and depression and aims to explore other areas of mental health including dissociative disorders such as maladaptive daydreaming.

Email: sabestian@pharma-geek.com

Latest posts by Sabestian Miller (see all)

• Enteral Feeding Devices: Valuable Niche in Medical Devices - November 18, 2022
• Largest Sleep Apnea Device Companies Between 2022 to 2027 - November 15, 2022
• Orthopedic Devices Market Size US$ 56.23 Bn By 2030 - November 14, 2022